Observation on the therapeutic effect of Salvia miltiorrhiza polyphenolate injection combined with tirofiban on patients with acute cerebral infarction

doi:10.11958/20241759

Abstract

Abstract:

Objective To investigate the influence of Salvia miltiorrhiza polyphenolate injection combined with tirofiban on the curative effect, macrophage migration inhibitory factor (MIF) level and hemorheology in patients with acute cerebral infarction (ACI). Methods A total of 116 patients with ACI were divided into the western medicine group (treated with tirofiban) and the combined group (treated with Salvia miltiorrhiza polyphenolate injection combined with tirofiban) by random number table method, with 58 cases in each group. Neurological deficit score (NIHSS) reduction was calculated, and the therapeutic effect was evaluated. Serum MIF, interleukin (IL)-6 and IL-1β levels were detected by enzyme-linked immunosorbent assay (ELISA) before and after treatment. Changes of hemorheological indexes (whole blood viscosity, whole blood low tangential viscosity and fibrinogen) of ACI patients were detected by SA-6600 automatic hemorheometer before and after treatment. The occurrence of adverse reactions during treatment was recorded. The modified Rankin Scale (mRS) was used to evaluate the clinical outcome at 90 days of onset, and the Barthel index was used to evaluate the living ability of the patients before and after treatment. Results The total clinical effective rate of ACI patients was higher in the combined group than that in the western medicine group (89.66% vs. 74.14%, P<0.05). After treatment, the levels of MIF, whole blood viscosity, whole blood low shear viscosity, fibrinogen, IL-6 and IL-1β were lower in 2 groups than those before treatment, and those were lower in the combined group than those in the western medicine group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). The Barthel index was higher after treatment in the two groups, and which was higher in the combined group than that of the western medicine group (P<0.05). The good outcome rate was higher in the combination group than that of the western medicine group (51.72% vs. 32.76%, P<0.05). Conclusion Salvia miltiorrhiza polyphenolate injection combined with tirofiban has a obvious effect for ACI patients, which can reduce serum levels of MIF and inflammatory factors, improve hemorheology indicators and has a high safety.

Key words: brain infarction, tirofiban, macrophage migration-inhibitory factors, hemorheology, salvia miltiorrhiza polyphenolate injection

CLC Number:

R285.6，R743.33

Figures/Tables 7

References 22

[1]	NAKAO K, YASUDA S, NISHIMURA K, et al. Prescription rates of guideline-directed medications are associated with in-hospital mortality among japanese patients with acute myocardial infarction:a report from JROAD-DPC study[J]. J Am Heart Assoc, 2019, 8(7):9692-9727. doi:10.1161/JAHA.118.009692.
[2]	许可, 安晓雷, 李晓宾, 等. 急性脑梗死患者发生血管性认知障碍的相关因素及预测模型构建[J]. 实用临床医药杂志, 2022, 26(6):1-5.
	XU K, AN X L, LI X B, et al. Related factors of vascular cognitive impairment in patients with acute cerebral infarction and establishment of prediction model[J]. Journal of Practical Clinical Medicine, 2022, 26(6):1-5. doi:10.7619/jcmp.20214684.
[3]	方悦琳, 张琳成, 姚奇谷, 等. 注射用丹参多酚酸盐联合依达拉奉治疗急性脑梗死疗效及安全性的Meta分析[J]. 浙江医学, 2021, 43(7):757-762,777.
	FANG Y L, ZHANG L C, YAO Q G, et al. Efficacy and safety of salvianolate injection combined with edaravone in treatment of acute cerebral infarction:a Meta-analysis[J]. Zhejiang Medicine, 2021, 43(7):757-762,777. doi:10.12056/j.issn.1006-2785.2021.43.7.2020-2876.
[4]	李永, 刘彬, 王荣. 替罗非班对急性脑梗死患者炎性因子及免疫功能的影响研究[J]. 重庆医学, 2021, 50(4):630-633.
	LI Y, LIU B, WANG R. Study on the effect of tirofiban on inflammatory factors and immune function in patients with acute cerebral infarction[J]. Chongqing Med, 2021, 50(4):630-633. doi:10.3969/j.issn.1671-8348.2021.04.020.
[5]	宋士更, 韩瑞丽, 王一旻. 急性脑梗死患者外周血MIF、TLR4水平与脑水肿严重程度的相关性[J]. 广东医学, 2021, 42(9):1119-1122.
	SONG S G, HAN R L, WANG Y M. Correlation between MIF and TLR4 levels in peripheral blood and the severity of cerebral edema in patients with acute cerebral infarction[J]. Guangdong Medicine, 2021, 42(9):1119-1122. doi:10.13820/j.cnki.gdyx.20193650.
[6]	高长玉, 吴成翰, 赵建国, 等. 中国脑梗死中西医结合诊治指南(2017)[J]. 中国中西医结合杂志, 2018, 38(2):136-144.
	GAO C Y, WU C H, ZHAO J G, et al. Chinese guidelines for the diagnosis and treatment of cerebral infarction with integrated traditional and western medicine (2017)[J]. CJITWM, 2018, 38(2):136-144. doi:10.7661/j.cjim.20171221.483.
[7]	罗凯, 高伟超, 郭仁光, 等. 益脑复健胶囊联合依达拉奉治疗急性脑梗死的临床研究[J]. 现代药物与临床, 2023, 38(3):607-611.
	LUO K, GAO W C, GUO R G, et al. Clinical study on yinao fujian capsules combined with edaravone in treatment of acute cerebral infarction[J]. Drugs & Clinic, 2023, 38(3):607-611. doi:10.7501/j.issn.1674-5515.2023.03.019.
[8]	中华医学会神经病学分会,中华医学会神经病学分会神经康复学组,中华医学会神经病学分会脑血管病学组. 中国脑卒中早期康复治疗指南[J]. 中华神经科杂志, 2017, 50(6):405-412.
	Chinese Society of Neurology,Chinese Society of Neurology,Neurological Rehabilitation Group,Chinese Society of Neurology,Cerebrovascular Disease Group. Chinese guidelines for early rehabilitation treatment of stroke[J]. Chinese Journal of Neurology, 2017, 50(6):405-412. doi:10.3760/cma.j.issn.1006-7876.2017.06.002.
[9]	许辉, 云宗金. 急性脑梗死患者机械取栓治疗后HT和转归不良的发生情况及危险因素分析[J]. 河北医学, 2021, 27(3):447-452.
	XU H, YUN Z J. Analysis of incidence and risk factors of adverse HT and prognosis in patients with acute cerebral infarction after mechanical thrombolysis[J]. Hebei Medical Journal, 2021, 27(3):447-452. doi:10.3969/j.issn.1006-6233.2021.03.020.
[10]	邱珍, 何泽会, 梁迎. 逐步控制性减压手术对急诊老年颅脑外伤患者术后转归的影响[J]. 老年医学与保健, 2022, 28(6):1267-1271.
	QIU Z, HE Z H, LIANG Y. Effects of stepwise controlled decompression on postoperative outcome of emergency elderly patients with craniocerebral trauma[J]. Geriatr Heal Care, 2022, 28(6):1267-1271. doi:10.3969/j.issn.1008-8296.2022.06.021.
[11]	YANG J, DUAN J, LI M, et al. Aldehyde dehydrogenase isoform 1 predicts a poor prognosis of acute cerebral infarction[J]. Contrast Media Mol Imaging, 2022, 2022(1):8199917-8199922. doi:10.1155/2022/8199917.
[12]	聂亚蒙, 张小强, 冯鹏展, 等. 依达拉奉右莰醇联合rt-PA静脉溶栓治疗超早期急性脑梗死的疗效及对预后的影响[J]. 天津医药, 2023, 51(7):766-771.
	NIE Y M, ZHANG X Q, FENG P Z, et al. Effect of Edaravone dextrocamphorol combined with rt-PA intravenous thrombolytic therapy on ultra-early acute cerebral infarction and its influence on prognosis[J]. Tianjin Med J, 2023, 51(7):766-771. doi:10.11958/20221607.
[13]	王诗颖, 方海姬, 谷娜, 等. 注射用丹参多酚酸盐联合常规西药治疗急性脑梗死有效性和安全性的系统评价[J]. 中国医院用药评价与分析, 2019, 19(7):860-864,868.
	WANG S Y, FANG H J, GU N, et al. Systematic evaluation on efficacy and safety of salvianolate injection combined with conventional western medicine in the treatment of acute cerebral infarction[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2019, 19(7):860-864,868. doi:10.14009/j.issn.1672-2124.2019.07.029.
[14]	黄洁, 骆嵩, 李金平, 等. 急性脑梗死血管内治疗后静脉注射替罗非班的安全性和有效性分析[J]. 中华全科医学, 2022, 20(5):766-769.
	HUANG J, LUO S, LI J P, et al. Safety and efficacy of intravenous tirofiban after endovascular treatment of acute cerebral infarction[J]. Chinese Journal of General Medicine, 2022, 20(5):766-769. doi:10.16766/j.cnki.issn.1674-4152.002449.
[15]	康梅娟, 温昌明, 刘义锋, 等. 丹红注射液联合替罗非班对急性脑梗死患者NF-κB炎症信号通路及疗效的影响[J]. 中国合理用药探索, 2020, 17(5):56-60.
	KANG M J, WEN C M, LIU Y F, et al. Effect of danhong injection and tirofiban on acute cerebral infarctionand associated NF-κB inflammation signal pathway[J]. Chinese Journal of Rational Drug Use, 2020, 17(5):56-60. doi:10.3969/j.issn.2096-3327.2020.5.013.
[16]	韩丽丽, 项蓉, 刘万根, 等. Solitaire AB支架取栓术联合替罗非班和丁苯酞对急性脑梗死患者神经功能和炎性因子的影响[J]. 中国临床研究, 2020, 33(4):488-492.
	HAN L L, XIANG R, LIU W G, et al. Effects of Solitaire AB stent thrombectomy combined with tirofiban and butylphthalide on neurologic function and inflammatory factors in patients with acute cerebral infarction[J]. Chin J Clin Res, 2020, 33(4):488-492. doi:10.13429/j.cnki.cjcr.2020.04.014.
[17]	姜川, 方旭, 冯建利, 等. 谷红注射液联合丹参多酚酸盐治疗急性脑梗死的临床研究[J]. 现代药物与临床, 2020, 35(7):1322-1326.
	JIANG C, FANG X, FENG J L, et al. Clinical study on guhong injection combined with salvianolic acid salt in treatment of acute cerebral infarction[J]. Drugs & Clinic, 2020, 35(7):1322-1326. doi:10.7501/j.issn.1674-5515.2020.07.007.
[18]	杨红玉, 陈金华, 谢春香. 注射用丹参多酚酸盐治疗急性脑梗死的临床疗效分析[J]. 中外医疗, 2021, 40(24):167-170.
	YANG H Y, CHEN J H, XIE C X. Analysis of clinical efficacy of salvia miltiorrhiza polyphenolate for injection in treating acute cerebral infarction[J]. Chinese and Foreign Medical Journal, 2021, 40(24):167-170. doi:10.16662/j.cnki.1674-0742.2021.24.167.
[19]	张志丹, 严广德. 探讨注射用丹参多酚酸盐治疗高龄冠心病心绞痛患者的临床疗效及对血脂、BNP、CRP水平的影响[J]. 中国实用医药, 2019, 14(34):108-110.
	To explore the clinical efficacy of injection of Danshen Polysaccharide Salts in the treatment of elderly patients with angina pectoris due to coronary heart disease and its influence on lipid,BNP and CRP levels[J]. China Practical Medicine, 2019, 14(34):108-110. doi:10.14163/j.cnki.11-5547/r.2019.34.057.
[20]	刘银芳, 曹心慧, 张晓曼. 注射用丹参多酚酸联合替罗非班对急性进展性脑梗死患者NIHSS评分和mRS评分的影响[J]. 药物评价研究, 2020, 43(8):1635-1638,1650.
	LIU Y F, CAO X H, ZHANG X M. Effect of salvianolic acids for injection combined with tirofiban on NIHSS and mRS scores in patients with acute progressive cerebral infarction[J]. Drug Eval Res, 2020, 43(8):1635-1638,1650. doi:10.7501/j.issn.1674-6376.2020.08.031.
[21]	马兵, 张丽红, 赵丹, 等. 急性髓系白血病患者巨噬细胞移动抑制因子表达水平及其与疗效、预后相关性分析[J]. 陕西医学杂志, 2021, 50(12):1558-1561.
	MA B, ZHANG L H, ZHAO D, et al. Expression level of macrophage migration inhibitory factor in AML patients and its correlation with curative effect and prognosis[J]. Shaanxi Medical Journal, 2021, 50(12):1558-1561. doi:10.3969/j.issn.1000-7377.2021.12.023.
[22]	赵红敏, 刘丽娜, 王静, 等. 丁苯酞联合丹参川芎嗪注射液治疗急性脑梗死的效果[J]. 中国医药, 2022, 17(4):514-517.
	ZHAO H M, LIU L N, WANG J, et al. Effect of butylphthalide combined with salviae miltiorrhizae and ligustrazine hydrochloride injection on acute cerebral infarction[J]. Chinese Medicine, 2022, 17(4):514-517. doi:10.3760/j.issn.1673-4777.2022.04.009.

组别	n		年龄/岁	性别				梗死部位
组别	n		年龄/岁	男		女		脑干		基底节		小脑
西药组	58		55.86±6.04	31（53.45）		27（46.55）		20（34.48）		28（48.28）		10（17.24）
联合组	58		56.38±6.61	26（44.83）		32（55.17）		19（32.76）		25（43.10）		14（24.14）
t或χ²			0.440	0.862				0.862
组别		体质量指数/（kg/m²）			基础疾病						NIHSS/分
组别		体质量指数/（kg/m²）			高血压		糖尿病		高脂血症		NIHSS/分
西药组		22.15±2.71			17（29.31）		10（17.24）		13（22.41）		14.67±3.62
联合组		22.03±2.43			15（25.86）		12（20.69）		14（24.14）		15.26±4.15
t或χ²		0.272			0.173		0.224		0.048		0.810

组别	n		年龄/岁	性别				梗死部位
组别	n		年龄/岁	男		女		脑干		基底节		小脑
西药组	58		55.86±6.04	31（53.45）		27（46.55）		20（34.48）		28（48.28）		10（17.24）
联合组	58		56.38±6.61	26（44.83）		32（55.17）		19（32.76）		25（43.10）		14（24.14）
t或χ²			0.440	0.862				0.862
组别		体质量指数/（kg/m²）			基础疾病						NIHSS/分
组别		体质量指数/（kg/m²）			高血压		糖尿病		高脂血症		NIHSS/分
西药组		22.15±2.71			17（29.31）		10（17.24）		13（22.41）		14.67±3.62
联合组		22.03±2.43			15（25.86）		12（20.69）		14（24.14）		15.26±4.15
t或χ²		0.272			0.173		0.224		0.048		0.810

组别	临床痊愈	显效	有效	无效	总有效
西药组	16（27.59）	13（22.41）	14（24.14）	15（25.86）	43（74.14）
联合组	26（72.41）	14（24.14）	12（20.69）	6（10.34）	52（89.66）

组别	临床痊愈	显效	有效	无效	总有效
西药组	16（27.59）	13（22.41）	14（24.14）	15（25.86）	43（74.14）
联合组	26（72.41）	14（24.14）	12（20.69）	6（10.34）	52（89.66）

组别	n	治疗前	治疗后	t
西药组	58	1.32±0.31	1.06±0.21	4.821^＊
联合组	58	1.35±0.33	0.85±0.16	10.361^＊
t		0.341	6.032^＊